Protealis Announces Regulatory Approval of its First Biological Solution MagNfix^TM and Launch of Five New Soybean Varieties

Ghent (Belgium), 11 March 2026 – Protealis, the European specialist in non-GMO legume seeds and seed technologies, today announces several milestones that significantly strengthen its position in a fast-growing European soybean market. The company has obtained European regulatory approval from EFCI¹ (EU Fertilising Products Regulation (FPR) 2019/1009) ​ for MagNfix™, its first biological solution, which is a proprietary soybean inoculant seed coating that is designed to support higher soybean yield and protein content. In addition, Protealis has secured the registration of five new soybean varieties across four European countries. This includes the introduction of two new maturity group (MG) 000 soybean varieties in Poland, the registration of its first maturity group 0000 ultra-early soybean variety in France, and a new soy variety registration for Belgium. In Germany, Protealis received registration for its second 00 MG soybean variety suited for the regions in southern Germany. With regulatory approval for its biological solution MagNfix^TM ​ and an expanding portfolio of high-performance, climate-adapted soybean varieties, Protealis is now fully geared to scale commercially with ready-to-sow soybean seeds to farmers across Europe in the years to come.

“With the European regulatory approval of MagNfix™, Protealis is entering the biologicals market alongside its core activity in soybean seed breeding and commercialization in Europe. The combination of an expanding portfolio of high-performance soybean varieties and a proprietary inoculant enables an integrated, ready-to-sow solution tailored to European growing conditions. This approach supports the economic viability of soybean cultivation in more northern regions and strengthens our position for further commercial expansion. This combination of ​ advanced genetics with proprietary biologicals can boost Europe’s domestic plant protein production in a way that works for farmers, economically and agronomically”, said David Buckeridge, Chairman of the Board of Directors of Protealis.

The European regulatory approval of MagNfix™, Protealis’ proprietary soybean seed inoculant, is a milestone for the company’s biologicals program. MagNfix™ incorporates a Bradyrhizobium bacteria strain selected for its adaptation to European soils and is applied through a seed coating technology. In independent multi-location registration trials, the product demonstrated yield increases of +31% on average compared to reference inoculants² and a +7% improvement in protein content versus peers². The formulation offers a shelf life of up to three months and is delivered as a ready-to-sow coated seed, eliminating the need for on-farm inoculation and delivering a time-efficient, scalable solution for large-scale farming operations.

At the same time, Protealis succeeded in the registration of five new soybean varieties which expand its portfolio from 9 varieties in 2025 to 14 today, spanning the 0000, 000 and 00 maturity groups. The new soybean varieties contain non-GMO soybean genetics specifically developed to thrive across colder northern and north-central European regions, including northern France, Germany and emerging eastern markets such as Poland. The new launches include PRO Hekla (MG 0000, France), the company’s first ultra-early MG 0000 variety suited to grow in colder areas in the north of France, while PRO Dinara and PRO Katla (MG 000, Poland) are marking Protealis’ commercial entry into Poland, one of Europe’s fastest-growing soybean markets reaching close to 100,000 hectares today. According to the Polish Soybean Association³, this area has doubled in the last two years, and has potential to reach up to 700,000 hectares. Furthermore, PRO Erebus is Protealis’ second MG 00 soybean variety registered in Germany, combining high yield with excellent early canopy coverage - a crucial trait that supports natural weed suppression. Lastly, PRO Bingo (MG 000, Belgium) strengthens its portfolio with excellent canopy closure and strong yield–protein balance. All five varieties consistently outperformed competitors in independent multi-location registration trials.

“This ​ is a pivotal moment for the company as we now see efforts of technology investment maturing in products and unique USPs that will enable profitable, local soybean cultivation right here in Europe,” said Benjamin Laga, CEO of Protealis. “For years, soybean acreage growth in Europe was constrained by the lack of high-performance varieties adapted to colder climates and by the absence of inoculant solutions truly suited to European soils. Protealis now addressed both of these challenges by combining climate-adapted genetics and advanced breeding technologies - including AI-driven selection - with our proprietary MagNfix™ inoculant into a ready-to-sow solution. This integrated approach enables farmers to cultivate locally adapted soybean varieties that contribute to crop rotation, soil health, and farm profitability.”

Following regulatory approval, Protealis will initiate a phased pre-commercial rollout during the current season with selected distribution partners in key markets including Poland, France and Germany, ahead of a broader commercial launch in 2027.

*** END ***

More information: ​
​Renate Degrave | Head of Communications and Marketing Protealis
​renate.degrave@protealis.com | +32 471 53 60 64

About Protealis

Protealis develops superior plant protein seeds and seed technologies, optimized for the European soil and climate. Being at the forefront of sustainable agriculture, Protealis aims to empower European farmers with sustainable and resilient alternatives to traditional protein sources by developing legume seed solutions with enhanced crop yield and protein levels, while at the same time minimizing the ecological footprint. By addressing the growing demand for more plant-based protein sources, the company is committed to contribute to more sustainable food systems. Today, Protealis operates as a commercial-stage company with 14 early-maturity soybean varieties currently on the market and registered in Belgium, France, Germany, Poland and Ukraine, and received European regulatory approval for MagNfix™, the company’s proprietary soybean seed inoculant. In parallel, the company is rapidly advancing its yellow pea breeding program within its development pipeline. The company is headquartered in the biotechnology cluster in Ghent, Belgium. More info on www.protealis.com, LinkedIn or facebook.

^{Data protection is important to us. You are receiving this publication on the legal basis of Article 6 para 1 lit. f GDPR ("legitimate interest"). However, if you do not wish to receive further information about Protealis, email us at info@protealis.com and we will no longer process your details for this purpose. You can also find further details in our privacy statement on www.protealis.com.}

^{Certain statements, beliefs and opinions in this press release are forward-looking, which reflect the Protealis’ (‘the Company’) or, as appropriate, the Company directors' or managements' current expectations and projections concerning future events such as the Company's results of operations, financial condition, liquidity, performance, prospects, growth, strategies and the industry in which the Company operates. By their nature, forward-looking statements involve a number of risks, uncertainties, assumptions and other factors that could cause actual results or events to differ materially from those expressed or implied by the forward-looking statements. These risks, uncertainties, assumptions and factors could adversely affect the outcome and financial effects of the plans and events described herein. A multitude of factors including, but not limited to, changes in demand, competition and technology, can cause actual events, performance or results to differ significantly from any anticipated development. Forward-looking statements contained in this press release regarding past trends or activities are not guarantees of future performance and should not be taken as a representation that such trends or activities will continue in the future. In addition, even if actual results or developments are consistent with the forward-looking statements contained in this press release, those results or developments may not be indicative of results or developments in future periods. No representations and warranties are made as to the accuracy or fairness of such forward-looking statements. As a result, the Company expressly disclaims any obligation or undertaking to release any updates or revisions to any forward-looking statements in this press release as a result of any change in expectations or any change in events, conditions, assumptions or circumstances on which these forward-looking statements are based, except if specifically required to do so by law or regulation. Neither the Company nor its advisers or representatives or any such person's officers or employees guarantees that the assumptions underlying such forward-looking statements are free from errors nor does either accept any responsibility for the future accuracy of the forward-looking statements contained in this press release or the actual occurrence of the forecasted developments. You should not place undue reliance on forward-looking statements, which speak only as of the date of this press release.}

^{[1] EFCI is the leading Notified Body for the EU Fertilising Products Regulation for FPR 2019/1009.}

^{[2] Measured after 1 month storage. Source: field trial data across different European locations.}

^{[3] Source: https://www.money.pl/gospodarka/polska-skrajnie-zalezna-od-importu-soi-zagrozenie-jest-powazne-7211788425362400a.html}